PharmaEssentia Corporation: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 19:3319:33, 23 September 2022 95.149.241.133 talk 994 bytes +994 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases in Taiwan and internationally. Its products include BESREMi (ropeginterferon alfa-2b) that is used for the treatment of chronic myelogenous leukemia, chronic neutrophilic leukemia, primary myelofibrosis, polycythemia vera, essential thrombocythemia, and hepatitis B and C; and Anti..."